Study Design and Baseline Characteristics of APOLLO : A Phase 3 Study of Bitopertin in Erythropoietic Protoporphyria and X‐Linked Protoporphyria
Year: 2026
Type: article
Abstract: ABSTRACT Erythropoietic protoporphyria (EPP) and X‐linked protoporphyria (XLP) are characterized by protoporphyrin IX (PPIX) accumulation, causing debilitating cutaneous phototoxic reactions and, in some cases, protoporphyric hepatopathy. Glycine transporter 1 (GlyT1) supplies extracellular glycine for erythroid heme biosynthesis. Bitopertin is an investigational oral GlyT1 inhibitor shown to significantly reduce PPIX and improve light tolerance and quality of life in patients with EPP or XLP. APOLLO is a global randomized, double‐blind, placebo‐controlled Phase 3 study designed to confirm the safety, tolerability, and efficacy of bitopertin in adults and adolescents with EPP or XLP. Eligible participants were ≥ 12 years of age with diagnosis by biochemical and/or genetic testing and randomized 1:1 to receive once‐daily oral bitopertin 60 mg or placebo over 24 weeks. Co‐primary endpoints are percent change in whole blood metal‐free PPIX and average monthly total time in sunlight on days without pain from a phototoxic reaction between 10:00 and 18:00 after 24 weeks. The general design and participants' baseline characteristics are described herein. Between April 2025 and March 2026, 199 patients were screened at 28 study sites in the United States, Canada, Europe, United Kingdom, and Australia; 183 participants were randomized. Mean (SD) age was 37.1 ± 17.1 years; 59% were female and 91% were White. Most participants (93%) had EPP, whereas 7% had XLP. Overall, 60% had not received prior treatment for EPP; 28% and 18% previously received afamelanotide or dersimelagon, respectively. Adolescents (12 to < 18 years) represented 19% of enrolled participants, and most adolescents (85%) had not previously received afamelanotide or dersimelagon. APOLLO is designed to evaluate bitopertin as a potential disease‐modifying therapy for EPP and XLP. Baseline demographic and disease characteristics were consistent with prior EPP/XLP and generally support the relevance of the study's safety and efficacy findings to the broader EPP/XLP population.
Source: The Journal of Dermatology
Authors: Amy Yeung, Mark Amster, Karl E. Anderson, Manisha Balwani, Herbert L. Bonkovsky, Edward Cordasco, Manuchehr Darani, Petra De Haes, Laurent Gouya, Siobán Keel, Ilja Kubisch, Janneke Langendonk, Cynthia Levy, Tasneem F. Mohammad, Manuel P. Pereira, Robert Sarkany, Bruce Wang, Melanie Chin, Will Savage, Gayle Ross, APOLLO Investigators
Institutions: Harvard University, Massachusetts General Hospital, The University of Texas Medical Branch at Galveston, Icahn School of Medicine at Mount Sinai, Atrium Health Wake Forest Baptist, Wake Forest University Health Sciences, Wake Forest University, Remington-Davis Clinical Research, Universitair Ziekenhuis Leuven, Université Paris Cité, University of Washington, Fred Hutch Cancer Center, Klinikum Chemnitz, Erasmus MC, University of Miami, Henry Ford Health, Humboldt-Universität zu Berlin, Freie Universität Berlin, Charité – Universitätsmedizin Berlin, University of California, San Francisco, Disc Medicine, Inc. (United States), The Royal Melbourne Hospital
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,630
OpenAlex ID: W7233552944
